Enveric Biosciences Inc Financials

ENVB

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Neutral

4/9

Enveric Biosciences Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.81x

For every $1 of reported earnings, Enveric Biosciences Inc generates $0.81 in operating cash flow (-$7.7M OCF vs -$9.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-43982.9x

Enveric Biosciences Inc earns $-43982.9 in operating income for every $1 of interest expense (-$9.6M vs $219). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Enveric Biosciences Inc (ENVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$9.3M

YoY+42.3%

Enveric Biosciences Inc's EBITDA was -$9.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 42.3% from the prior year.

Free Cash Flow

N/A

Net Income

-$9.6M

YoY+44.6%

Enveric Biosciences Inc reported -$9.6M in net income in fiscal year 2024. This represents an increase of 44.6% from the prior year.

EPS (Diluted)

$-19.04

Enveric Biosciences Inc earned $-19.04 per diluted share (EPS) in fiscal year 2024. This represents an increase of 84.3% from the prior year.

Cash & Debt

$2.2M

YoY-2.1%

5Y CAGR+39.0%

10Y CAGR+19.6%

Enveric Biosciences Inc held $2.2M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

56,501

Enveric Biosciences Inc had 56,501 shares outstanding in fiscal year 2024. This represents a decrease of 69.1% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$2.8M

YoY-60.8%

Enveric Biosciences Inc invested $2.8M in research and development in fiscal year 2024. This represents a decrease of 60.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ENVB Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	$39.9M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$31.8M
Gross Profit	N/A	N/A	N/A	N/A	N/A	$8.2M
R&D Expenses	$2.8M-60.8%	$7.3M-9.7%	$8.0M+67.6%	$4.8M+2650.9%	$174K	N/A
SG&A Expenses	$6.5M-27.1%	$8.9M-23.7%	$11.6M-43.4%	$20.5M+285.1%	$5.3M+131.8%	$2.3M
Operating Income	-$9.6M+41.4%	-$16.4M+40.0%	-$27.4M+57.6%	-$64.6M-1050.4%	-$5.6M-144.6%	-$2.3M
Interest Expense	$219-94.1%	$4K-29.4%	$5K-49.1%	$10K-97.7%	$445K+444.2%	$82K
Income Tax	$9K-69.1%	$29K+101.9%	-$1.5M+80.1%	-$7.5M	N/A	$389K
Net Income	-$9.6M+44.6%	-$17.3M+6.4%	-$18.5M+62.3%	-$49.0M-613.5%	-$6.9M-184.8%	-$2.4M
EPS (Diluted)	$-19.04	$-121.29	$-13.00	N/A	N/A	$-2.83

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$402K-49.9%	$803K	N/A	$1.3M	N/A	$2.1M	N/A	$1.2M
SG&A Expenses	$1.4M+19.7%	$1.2M	N/A	$2.1M	N/A	$3.5M	N/A	$2.1M
Operating Income	-$1.9M+10.0%	-$2.1M	N/A	-$3.4M	N/A	-$5.7M	N/A	-$3.5M
Interest Expense	$274+226.3%	-$217	N/A	$2K	N/A	$308	N/A	$370
Income Tax	N/A	$2K	N/A	$7K	N/A	N/A	N/A	N/A
Net Income	-$1.9M+10.1%	-$2.1M	N/A	-$2.8M	N/A	-$2.5M	N/A	-$2.7M
EPS (Diluted)	$-10.81	$-43.10	N/A	$-1.30	N/A	$-1.46	N/A	N/A

ENVB Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$3.1M-28.3%	$4.3M-78.0%	$19.6M-26.8%	$26.7M+552.2%	$4.1M+3665.9%	$109K
Current Assets	$2.7M-23.6%	$3.6M-80.6%	$18.4M+3.9%	$17.7M+678.2%	$2.3M+1995.0%	$109K
Cash & Equivalents	$2.2M-2.1%	$2.3M-87.1%	$17.7M+2.1%	$17.4M+999.6%	$1.6M+265.9%	$431K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$6.4M
Goodwill	N/A	N/A	$380K-76.1%	$1.6M	N/A	$13.7M
Total Liabilities	$1.5M-36.4%	$2.3M-41.4%	$4.0M-9.5%	$4.4M+547.8%	$681K-64.5%	$1.9M
Current Liabilities	$1.5M-36.4%	$2.3M-41.4%	$4.0M+46.0%	$2.7M+301.8%	$681K-95.0%	$13.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$740K
Total Equity	$1.6M-18.6%	$2.0M-86.7%	$14.7M-34.2%	$22.3M+553.1%	$3.4M+288.5%	-$1.8M
Retained Earnings	-$106.1M-9.9%	-$96.5M-21.8%	-$79.2M-30.4%	-$60.7M-416.5%	-$11.8M-140.2%	-$4.9M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Total Assets	$4.4M+41.5%	$3.1M-28.3%	$4.3M-35.0%	$6.6M-66.1%	$19.6M-36.6%	$30.9M+15.5%	$26.7M-61.7%	$69.8M
Current Assets	$4.2M+52.3%	$2.7M-23.6%	$3.6M-38.5%	$5.8M-68.4%	$18.4M-17.2%	$22.3M+25.5%	$17.7M-20.4%	$22.3M
Cash & Equivalents	$3.8M+67.7%	$2.2M-2.1%	$2.3M-46.4%	$4.3M-75.9%	$17.7M-16.4%	$21.2M+22.2%	$17.4M-19.1%	$21.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$253K-33.3%	$380K-74.1%	$1.5M-7.5%	$1.6M-82.5%	$9.1M
Total Liabilities	$906K-39.2%	$1.5M-36.4%	$2.3M-44.0%	$4.2M+4.7%	$4.0M-44.9%	$7.3M+64.4%	$4.4M-69.3%	$14.4M
Current Liabilities	$906K-39.2%	$1.5M-36.4%	$2.3M-44.0%	$4.2M+4.7%	$4.0M+53.8%	$2.6M-5.1%	$2.7M+26.6%	$2.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.5M+117.0%	$1.6M-18.6%	$2.0M-19.7%	$2.4M-83.4%	$14.7M-35.8%	$22.8M+2.4%	$22.3M-59.7%	$55.4M
Retained Earnings	-$112.7M-6.2%	-$106.1M-9.9%	-$96.5M-3.7%	-$93.1M-17.5%	-$79.2M-12.3%	-$70.5M-16.1%	-$60.7M-226.0%	-$18.6M

ENVB Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$7.7M+45.2%	-$14.1M+17.8%	-$17.1M-49.7%	-$11.5M-194.6%	-$3.9M-500.3%	-$648K
Capital Expenditures	N/A	$5K-99.1%	$584K+207.9%	$190K	N/A	N/A
Free Cash Flow	N/A	-$14.1M+20.5%	-$17.7M-52.2%	-$11.6M	N/A	N/A
Investing Cash Flow	N/A	$12K+102.0%	-$584K-126.7%	$2.2M+5062.5%	-$44K+84.5%	-$284K
Financing Cash Flow	$7.7M+671.3%	-$1.3M-107.4%	$18.2M-27.0%	$24.9M+350.2%	$5.5M+887.7%	$560K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Operating Cash Flow	-$2.1M-58.2%	-$1.3M+25.1%	-$1.8M+36.1%	-$2.7M+20.8%	-$3.5M+23.9%	-$4.6M-11.9%	-$4.1M-84.4%	-$2.2M
Capital Expenditures	N/A	N/A	-$15-287.5%	$8-99.9%	$6K-66.7%	$19K	N/A	N/A
Free Cash Flow	N/A	N/A	-$1.8M+36.1%	-$2.7M+21.0%	-$3.5M+24.1%	-$4.6M	N/A	N/A
Investing Cash Flow	N/A	N/A	-$38-290.0%	$20+100.3%	-$6K+66.7%	-$19K+90.2%	-$190K-106.2%	$3.1M
Financing Cash Flow	$3.0M+545.7%	$463K+349.1%	-$186K-77.2%	-$105K-10499900.0%	-$1-100.0%	$7.8M+111774414.3%	$7+177.8%	-$9
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ENVB Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	20.4%
Operating Margin	N/A	N/A	N/A	N/A	N/A	-5.8%
Net Margin	N/A	N/A	N/A	N/A	N/A	-6.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-310.6%+91.5pp	-402.1%-307.7pp	-94.5%+88.8pp	-183.3%-15.7pp	-167.6%+2048.4pp	-2215.9%
Current Ratio	1.84+0.3	1.53-3.1	4.61-1.9	6.48+3.1	3.35+3.3	0.01
Debt-to-Equity	0.94-0.3	1.20+0.9	0.27+0.1	0.200.0	0.20+0.6	-0.41
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-43.0%+0.6pp	-43.5%	N/A	-42.6%	N/A	-8.0%	N/A	-3.9%
Current Ratio	4.60+2.8	1.84+0.3	1.53+0.1	1.39-3.2	4.61-4.0	8.57+2.1	6.48-3.8	10.30
Debt-to-Equity	0.26-0.7	0.94-0.3	1.20-0.5	1.72+1.4	0.27-0.0	0.32+0.1	0.20-0.1	0.26
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Unity Btech UBX

$5.1M

Indaptus Therapeutics Inc INDP

$3.7M

Qualigen Therapeutics Inc QLGN

$6.5M

Revelation Biosciences REVB

$3.8M

Protagenic Therapeutics Inc PTIX

$1.4M

Frequently Asked Questions

Is Enveric Biosciences Inc profitable?

No, Enveric Biosciences Inc (ENVB) reported a net income of -$9.6M in fiscal year 2024.

What is Enveric Biosciences Inc's earnings per share (EPS)?

Enveric Biosciences Inc (ENVB) reported diluted earnings per share of $-19.04 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Enveric Biosciences Inc's EBITDA?

Enveric Biosciences Inc (ENVB) had EBITDA of -$9.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Enveric Biosciences Inc's operating cash flow?

Enveric Biosciences Inc (ENVB) generated -$7.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Enveric Biosciences Inc's total assets?

Enveric Biosciences Inc (ENVB) had $3.1M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Enveric Biosciences Inc spend on research and development?

Enveric Biosciences Inc (ENVB) invested $2.8M in research and development during fiscal year 2024.

How many shares does Enveric Biosciences Inc have outstanding?

Enveric Biosciences Inc (ENVB) had 56,501 shares outstanding as of fiscal year 2024.

What is Enveric Biosciences Inc's current ratio?

Enveric Biosciences Inc (ENVB) had a current ratio of 1.84 as of fiscal year 2024, which is generally considered healthy.

What is Enveric Biosciences Inc's debt-to-equity ratio?

Enveric Biosciences Inc (ENVB) had a debt-to-equity ratio of 0.94 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Enveric Biosciences Inc's return on assets (ROA)?

Enveric Biosciences Inc (ENVB) had a return on assets of -310.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Enveric Biosciences Inc's cash runway?

Based on fiscal year 2024 data, Enveric Biosciences Inc (ENVB) had $2.2M in cash against an annual operating cash burn of $7.7M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Enveric Biosciences Inc's Piotroski F-Score?

Enveric Biosciences Inc (ENVB) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Enveric Biosciences Inc's earnings high quality?

Enveric Biosciences Inc (ENVB) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Enveric Biosciences Inc cover its interest payments?

Enveric Biosciences Inc (ENVB) has an interest coverage ratio of -43982.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.